Peregrine Pharma (PPHM) Reports In-Line Q1 EPS

Peregrine Pharma (NASDAQ: PPHM) reported Q1 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $5.82 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
• KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance
• York Space Systems, Inc. (YSS) Reports Q2 Loss of $0.31 ; Offers Guidance